Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    ClinicalTrials.gov’s page footer release/version indicator advanced from **v3.5.2** to **v3.5.3**.
    Difference
    0.1%
    Check dated 2026-04-25T06:15:18.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Page revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-18T03:54:11.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    No substantive content changes detected. The page appears the same aside from minor visual/layout adjustments.
    Difference
    0.1%
    Check dated 2026-04-03T19:24:27.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    No detectable content changes between the old and new screenshots; the study details, eligibility criteria, and outcomes sections appear consistent.
    Difference
    0.1%
    Check dated 2026-03-27T13:23:40.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    The page now shows a new document revision labeled v3.5.0 and removes the earlier v3.4.3 revision, indicating updated study documents are available.
    Difference
    0.1%
    Check dated 2026-03-20T07:39:26.000Z thumbnail image
  8. Check
    62 days ago
    Change Detected
    Summary
    Results for the Phase I/II study of anti-CD3 x anti-HER2/Neu BATs with Pembrolizumab in metastatic breast cancer were posted, detailing dose-limiting toxicities, response rates, survival metrics, and immune monitoring data. Related study documents, including the Study Protocol and Informed Consent Form, were added.
    Difference
    3%
    Check dated 2026-03-05T23:26:40.000Z thumbnail image

Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.